Douglas Scharre, MD
Neurology · Columbus, OHNPI 1205910502
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $142,826 of the $190,717 with a category attached, or 74.9%. 10 manufacturers reported payments, led by Eisai Inc. at 29.2% of the total. Among neurology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $1135.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$56K
- Lilly USA, LLC$53K
- Biogen$38K
- Acadia Pharmaceuticals Inc$22K
- Eli Lilly$12K
- Otsuka America Pharmaceutical, Inc.$7K
- plus $3K from 4 others
Across 333 payments — averaging $19,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.3M
- Eisai Inc.$1.6M
- Genentech, Inc.$1.1M
- Biogen$810K
- Janssen Research & Development, LLC$581K
- E.r. Squibb & Sons, L.L.C.$108K
- plus $165K from 6 others
What the payments were for
- Consulting fees$142,82675%
- Speaking & faculty fees$33,21817%
- Travel & lodging$11,9026%
- Food & beverage$2,7721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 70 | $55,647 |
| Lilly USA, LLC | 48 | $52,628 |
| Biogen | 16 | $37,687 |
| Acadia Pharmaceuticals Inc | 13 | $21,877 |
| Eli Lilly | 8 | $12,489 |
| Otsuka America Pharmaceutical, Inc. | 4 | $7,045 |
| Novo Nordisk | 1 | $2,180 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $975 |
| Genentech USA, Inc. | 1 | $111 |
| F. Hoffmann-la Roche AG | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$190,717 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,524 |
| Memantine Hcl | 200 | $6,871 |
| Donepezil Hcl | 382 | $6,198 |
| Galantamine ErGalantamine Hbr | 65 | $5,789 |
| Rivastigmine | 41 | $5,349 |
| Divalproex Sodium | 171 | $4,588 |
| Quetiapine Fumarate | 149 | $3,021 |
| Carbamazepine | 91 | $2,017 |
| Memantine Hcl ErMemantine Hcl | 15 | $1,851 |
| Mirtazapine | 81 | $1,568 |
| Sertraline Hcl | 127 | $1,557 |
| Ziprasidone Hcl | 27 | $1,315 |
| Galantamine Hbr | 20 | $1,162 |
| Gabapentin | 94 | $1,124 |
| Escitalopram Oxalate | 66 | $882 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Allison JordanColumbus$98K
- Aram ZabetiCincinnati$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.